Sci-Tech Portal St. Lucia: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Portal St. Lucia.

September 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Press releases published on October 18, 2025

October 18, 2025

Free Welcome Bonus No Deposit Required Real Money Online Casino By Cafe Casino

GlobeNewswire

October 18, 2025

Crypto Casino No Deposit Bonus | Bitcoin Casino No Deposit Bonus 2025 By Cafe Casino

GlobeNewswire

October 18, 2025

Free Spins No Deposit UK | Real Money Online Casino In UK By Cafe Casino

GlobeNewswire

October 18, 2025

Fast Payout Casinos 2025: All iGaming Releases Exclusive Update on the Instant Withdrawal Casinos

GlobeNewswire

October 18, 2025

DeFi crypto Mutuum Finance (MUTM) Onboards Over 17,300 Investors With 70% of Phase 6 Allocated

GlobeNewswire

October 18, 2025

iFLYTEK AINOTE 2 kommt auf den Markt: Eine bahnbrechende Neuerung für die Produktivität im Beruf

GlobeNewswire

October 18, 2025

Lancement de l’iFLYTEK AINOTE 2 : véritable révolution pour la productivité professionnelle

GlobeNewswire

October 18, 2025

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

GlobeNewswire

October 18, 2025

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

GlobeNewswire

October 18, 2025

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

GlobeNewswire

October 18, 2025

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

GlobeNewswire

October 18, 2025

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

GlobeNewswire

October 18, 2025

General Oncology Announces Promising Preliminary Phase 1 Results from SHARON Trial Presented at ESMO 2025

GlobeNewswire

October 18, 2025

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

GlobeNewswire